MYO19: A Potential Drug Target for Muscle-Related Diseases (G80179)

Target Name: MYO19

NCBI ID: G80179

MYO19

MYO19: A Potential Drug Target for Muscle-Related Diseases

Myosin XIX (MYO19) is a protein that plays a critical role in muscle contractions and relaxation. It is a member of the myosin family, which is known for their role in the regulation of muscle strength and function.MYO19 is a key regulator of muscle myosin ATPase (Myosin ATPase), which is the protein that powers muscle contractions. It is a protein that is expressed in high abundance in muscle tissues, including skeletal muscles, heart, and lens.

MYO19 function

MYO19 is a 19 kDa protein that is expressed in muscle tissues. It is a key regulator of muscle myosin ATPase, which is the protein that powers muscle contractions.ATPase is a transmembrane protein that is composed of two subunits, alpha and beta. The alpha subunit is the motor protein that is responsible for the power of the myosin ATPase reaction. The beta subunit is a protein that interacts with the alpha subunit to regulate the activity of the myosin ATPase.

MYO19 plays a critical role in the regulation of muscle strength and function. It is involved in the regulation of muscle contractions, muscle relaxation, and the maintenance of muscle integrity. It is also involved in the regulation of the growth and differentiation of muscle fibers.

MYO19 is a potential drug target

MYO19 is a protein that is involved in many critical processes in the regulation of muscle strength and function. As a result, it is a potential drug target.

One of the main potential drug targets for MYO19 is the treatment of muscle-related diseases, such as myopathies. Myopathies are a group of diseases that are characterized by muscle weakness and dysfunction. These diseases can be caused by a variety of factors, including genetic and environmental factors.

MYO19 has been shown to be involved in the regulation of muscle strength and function, which makes it a potential drug target for the treatment of myopathies. Several studies have shown that inhibiting the activity of MYO19 can improve muscle strength and function in individuals with myopathies.

Another potential drug target for MYO19 is the treatment of muscle injuries. Muscle injuries can be caused by a variety of factors, including trauma, inflammation, or muscle overuse.

MYO19 has been shown to be involved in the regulation of muscle strength and function, which makes it a potential drug target for the treatment of muscle injuries. Several studies have shown that administering MYO19 inhibitors to individuals with muscle injuries can improve muscle strength and function.

MYO19 is also a potential biomarker for muscle-related diseases. The level of MYO19 is often reduced in individuals with muscle-related diseases, which can be used as a diagnostic marker for these diseases.

Conclusion

MYO19 is a protein that plays a critical role in the regulation of muscle strength and function. It is a member of the myosin family and is expressed in high abundance in muscle tissues.MYO19 is involved in the regulation of muscle myosin ATPase, which is the protein that powers muscle contractions.

MYO19 is a potential drug target for the treatment of muscle-related diseases and for the treatment of muscle injuries. It is also a potential biomarker for these diseases. Further research is needed to fully understand the role of MYO19 in the regulation of muscle strength and function, and to develop effective treatments for these diseases.

Protein Name: Myosin XIX

Functions: Actin-based motor molecule with ATPase activity that localizes to the mitochondrion outer membrane (PubMed:19932026, PubMed:23568824, PubMed:25447992). Motor protein that moves towards the plus-end of actin filaments (By similarity). Required for mitochondrial inheritance during mitosis (PubMed:25447992). May be involved in mitochondrial transport or positioning (PubMed:23568824)

The "MYO19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYO19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets